The Perfect Enemy | Category: Social Impact | Page 399
September 18, 2025

Social Impact

Atriva Therapeutics announces Topline Results from the Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with COVID-19

EQS-News: Atriva Therapeutics GmbH / Key word(s): Study results/Research UpdateAtriva Therapeutics announces Topline Results from the Proof of Concept (POC)...